Literature DB >> 16855075

Population pharmacokinetics of amlodipine in hypertensive children and adolescents.

Joseph T Flynn1, Milap C Nahata, John D Mahan, Ronald J Portman.   

Abstract

A population pharmacokinetic study was conducted in 74 hypertensive children (mean age 10.4 +/- 4.4 years [mean +/- SD]) receiving amlodipine (mean dose 0.17 +/- 0.13 mg/kg/d) chronically. Multiple blood samples were obtained from each subject to characterize amlodipine pharmacokinetics. Plasma amlodipine concentrations were determined by liquid chromatography/mass spectrophotometry with multiple-reaction monitoring detection. Population pharmacokinetic analysis was performed using NONMEM. Amlodipine concentrations were similar in subjects dosed either once or twice daily. Amlodipine pharmacokinetics were well described by a 1-compartment model with first-order absorption and elimination. For a subject at the population median weight (45 kg), predicted apparent clearances (CL/F) were 23.7 L/h for males and 17.6 L/h for females, and the apparent volume of distribution (V/F) was 25.1 L/kg. Dosing frequency did not appear to affect amlodipine concentrations in children. Weight-adjusted CL/F and V/F of amlodipine in younger children were significantly greater than in older children, suggesting a need for higher doses when treating young children with amlodipine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16855075     DOI: 10.1177/0091270006289844

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  12 in total

1.  Interplay between pediatric pharmacy practice and research to influence patient care.

Authors:  Milap C Nahata
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

2.  Random sparse sampling strategy using stochastic simulation and estimation for a population pharmacokinetic study.

Authors:  Xiao-Hui Huang; Kun Wang; Ji-Han Huang; Ling Xu; Lu-Jin Li; Yu-Cheng Sheng; Qing-Shan Zheng
Journal:  Saudi Pharm J       Date:  2013-02-10       Impact factor: 4.330

3.  Treating Hypertension in Children With n-of-1 Trials.

Authors:  Joyce P Samuel; Jon E Tyson; Charles Green; Cynthia S Bell; Claudia Pedroza; Don Molony; Joshua Samuels
Journal:  Pediatrics       Date:  2019-03-06       Impact factor: 7.124

Review 4.  Pharmacologic Management of Pediatric Hypertension.

Authors:  Jason Misurac; Kristen R Nichols; Amy C Wilson
Journal:  Paediatr Drugs       Date:  2016-02       Impact factor: 3.022

5.  Quantitative model for the blood pressure-lowering interaction of valsartan and amlodipine.

Authors:  Young-A Heo; Nick Holford; Yukyung Kim; Mijeong Son; Kyungsoo Park
Journal:  Br J Clin Pharmacol       Date:  2016-10-03       Impact factor: 4.335

6.  Prospective change in renal volume and function in children with ADPKD.

Authors:  Melissa A Cadnapaphornchai; Kim McFann; John D Strain; Amirali Masoumi; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2009-04       Impact factor: 8.237

7.  Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.

Authors:  Perrine Courlet; Monia Guidi; Susana Alves Saldanha; Matthias Cavassini; Marcel Stoeckle; Thierry Buclin; Catia Marzolini; Laurent A Decosterd; Chantal Csajka
Journal:  Eur J Clin Pharmacol       Date:  2021-01-16       Impact factor: 2.953

8.  Short- and long-term physiologic and pharmacologic control of blood pressure in pediatric patients.

Authors:  Howard Trachtman
Journal:  Integr Blood Press Control       Date:  2011-05-24

9.  Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model.

Authors:  Dwaipayan Mukherjee; Jiuhong Zha; Rajeev M Menon; Mohamad Shebley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-02-09       Impact factor: 2.745

10.  Comparative effectiveness of antihypertensive treatment for older children with primary hypertension: study protocol for a series of n-of-1 randomized trials.

Authors:  Joyce P Samuel; Joshua A Samuels; Lauren E Brooks; Cynthia S Bell; Claudia Pedroza; Donald A Molony; Jon E Tyson
Journal:  Trials       Date:  2016-01-08       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.